5 research outputs found
The Chemogenetic Receptor Ligand Clozapine N-Oxide Induces<em> in vivo</em> Neuroreceptor Occupancy and Reduces Striatal Glutamate Levels
Chemogenetic studies with the ligand clozapine N-oxide (CNO) are predicated upon
the assumption that CNO is devoid of actions at natural neuroreceptors. However,
recent evidence shows that CNO may be converted back to clozapine (CLZ) in vivo,
which could yield plasma concentrations that may be sufficient to occupy inter alia
dopamine D2=3 and serotonin 5HT2A receptors in living brain. To test this phenomenon,
we measured striatal dopamine D2=3 receptor occupancy with [18F]fallypride PET
and serotonin 5HT2A occupancy ex vivo using [18F]MH.MZ. We found a CNO dosedependent effect on the availability of both neuroreceptor sites. In parallel MR
spectroscopy experiments, we found that CNO reduced creatine C phosphcreatine
(CrCPCr) and increased N-acetylaspartate C N-acetylaspartylglutamate (NAACNAAG)
signals in the prefrontal cortex, and also reduced the glutamate signal in dorsal striatum,
with peak effect at 2 mg/kg. Thus, our findings suggest that conversion of CNO to CLZ in
living rats imparts significant occupancy at endogenous neuroreceptors and significant
changes to neurometabolite levels
Improved radiosynthesis and preliminary in vivo evaluation of the <sup>11</sup> C-labeled tetrazine [ <sup>11</sup> C]AE-1 for pretargeted PET imaging
Towards selective CNS PET Imaging of the 5-HT<sub>7</sub> Receptor System:Past, Present and Future
Classics in Neuroimaging:The Serotonergic 2A Receptor System-from Discovery to Modern Molecular Imaging
Blocking of efflux transporters in rats improves translational validation of brain radioligands
Background Positron emission tomography (PET) is a molecular imaging technique that can be used to investigate the in vivo pharmacology of drugs. Initial preclinical evaluation of PET tracers is often conducted in rodents due to the accessibility of disease models as well as economic considerations. Compared to larger species, rodents display a higher expression and/or activity of efflux transporters such as the P-glycoprotein (P-gp). Low brain uptake could, therefore, be species-specific and uptake in rodents not be predictive for that in humans. We hypothesized that a better prediction from rodent data could be achieved when a tracer is evaluated under P-gp inhibition. Consequently, we compared the performance of eight neuroreceptor tracers in rats with and without P-gp inhibition including a specific binding blockade. This data set was then used to predict the binding of these eight tracers in pigs. Methods PET tracers targeting serotonin 5-HT(2A)receptors ([F-18]MH.MZ, [F-18]Altanserin, [C-11]Cimbi-36, [C-11]Pimavanserin), serotonin 5-HT(7)receptors ([C-11]Cimbi-701, [C-11]Cimbi-717 and [C-11]BA-10) and dopamine D(2/3)receptors ([F-18]Fallypride) were used in the study. The brain uptake and target-specific binding of these PET radiotracers were evaluated in rats with and without inhibition of P-gp. Rat data were subsequently compared to the results obtained in pigs. Results Without P-gp inhibition, the amount of target-specific binding in the rat brain was sufficient to justify further translation for three out of eight evaluated tracers. With P-gp inhibition, results for five out of eight tracers justified further translation. The performance in pigs could correctly be predicted for six out of eight tracers when rat data obtained under P-gp inhibition were used, compared to four out of eight tracers without P-gp inhibition. Conclusions P-gp strongly affects the uptake of PET tracers in rodents, but false prediction outcomes can be reduced by evaluating a tracer under P-gp inhibition